GlassScriptPhysician profile
Marisa D Argubright
NPI 1245679760
$4,969.84
in general payments reported to CMS, 2019-2025
54 companies · $702 in 2025
The $702 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $107 · 2021: $740 · 2022: $1,107 · 2023: $828 · 2024: $819 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.34 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Novo Nordisk INC | $795.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $313.91 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $273.79 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.03 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $168.57 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Otsuka America Pharmaceutical, INC. | $136.02 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.16 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $113.15 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $93.24 | 2021-2022 | |
| Dexcom, INC. | $87.90 | 2022-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $85.46 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $83.90 | 2019-2023 | |
| Abbott Laboratories | $78.52 | 2023-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $77.86 | 2021 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Argubright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.